Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05166382 · ClinicalTrials.gov registry record · NA
Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications
A NA study of Type 2 Diabetes and Cardiovascular Diseases, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- NA
- Development phase
- 350
- Enrollment target
- 1
- Study location
NCT05166382: Completed NA study of Type 2 Diabetes and Cardiovascular Diseases, sponsored by University of Colorado, Denver.
NCT05166382 is a NA study of Type 2 Diabetes and Cardiovascular Diseases that has completed, run by University of Colorado, Denver. The registered enrollment target is 350 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05166382, a NA study of Type 2 Diabetes and Cardiovascular Diseases, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn more about using a proteomic test called the SomaSignal Cardiovascular (CV) Risk Test in Type 2 Diabetes (CVD-T2D) to improve medical care for patients.
Primary Outcome
Determine whether risk stratification results from SomaLogic's CVDT2D test leads to risk concordant changes in prescriptions and/or medical management through a patient and provider completed questionnaire. Questionnaire is a binary measurement of "prescribed medicine?" with possible answers "Yes" or "No". Number of participants prescribed medication will be reported.
Conditions Studied
Interventions
- BEHAVIORAL Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)
- BEHAVIORAL Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)
Study Locations (1)
Colorado
- Aanchal Gupta - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2022-01-01 |
| Est. Completion | 2024-01-01 |
| Phase | NA |
What the finished NCT05166382 record still lists
NCT05166382 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D) is the first listed.
NCT05166382 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT05166382 about?
NCT05166382 is a clinical study titled "Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications". The purpose of this study is to learn more about using a proteomic test called the SomaSignal Cardiovascular (CV) Risk Test in Type 2 Diabetes (CVD-T2D) to improve medical care for patients.
What is the current status of trial NCT05166382?
This trial is currently completed. It is a NA study. The enrollment target is 350 participants. The study started on 2022-01-01. Estimated completion is 2024-01-01.
What conditions does trial NCT05166382 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Cardiovascular Diseases.
What interventions are being tested in trial NCT05166382?
The interventions under investigation include: Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D) (BEHAVIORAL), Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05166382?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05166382 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05166382's enrollment target sits among peer trials
350 59th of 327 higher than 269 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI